RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Gusto Global, a leading microbiome discovery platform company focused on restoring a healthy microbiome, has developed novel consortia of bacteria that shows promise as a “breakthrough” therapy for treating Crohn’s disease and ulcerative colitis in patients.
A new study published this month in Nature Communications by Gusto Global and top UNC-Chapel Hill scientists demonstrated that the live bacterial consortia, called GUT-103 and GUT-108, prevented and treated chronic immune-mediated colitis in humanized mouse models.
“Best-in-class preclinical results for a Live Biotherapeutic Product validate Gusto’s bottom-up rational consortium design approach that is rigorously informed by mechanistic modeling and insights from microbiome ecology and disease pathogenesis,” said Dr. Daniel van der Lelie, Gusto Global’s CEO.
Crohn’s disease and ulcerative colitis are both forms of inflammatory bowel diseases (IBD). They affect at least 1.6 million Americans, most of whom are diagnosed before age 30. These chronic, life-long conditions can be treated but not cured.
“This design of the optimal microbiome restoration therapy takes sharp aim at root causes and is a significant breakthrough for the microbiome field which lacks mechanistic understanding,” van der Lelie said.
GUT-103 is comprised of 17 strains of bacteria that work together to protect and feed each other. GUT-108 is a refined version of GUT-103, using 11 human isolates related to the 17 strains. These combinations permit the bacteria to stay in the colon for an extended amount of time, as opposed to other probiotics that are not capable of living in the gut and pass through the system quickly.
In the study conducted at UNC-Chapel Hill, GUT-103 and GUT-108 were given orally three times a week to “germ-free” mice (no bacteria present) that were colonized either by specific human bacteria, or a fecal transplant from a healthy donor, to create a “humanized” mouse model of moderate to severe colitis.
“The idea of this treatment is to restore the normal function of the protective intestinal bacteria by targeting the underlying cause of IBD, instead of treating its symptoms with traditional immunosuppressants that can cause side effects like infections or tumors,” said a senior author, Balfour Sartor, MD, Midget Distinguished Professor of Medicine, Microbiology and Immunology, Co-Director of the UNC Center for Gastrointestinal Biology and Disease.
“It also decreased pathobionts -- bacteria that can cause harm -- while expanding resident protective bacteria, and produced metabolites promoting mucosal healing and immunoregulatory responses,” Sartor added.
Gusto Global’s deep characterization of microbiomes and clear therapeutic design thinking represent the frontier of microbiome innovation. GUT-108 is expected to advance into Phase 1 clinical trial.
This work was funded by Gusto Global, LLC. Germ-free mice were provided by grants from the National Institutes of Health (NIH), and the Crohn’s and Colitis Foundation.
About Gusto Global:
Founded in 2016, Gusto Global is the leading microbiome discovery platform company focused on understanding the dynamics of human microbial ecosystems and developing targeted solutions. Gusto’s proprietary GUST+ bioinformatics, computational modeling and predictive analytics platform uses advanced metagenomics-based analysis to interpret dynamic molecular communication, both within microbial communities and in their mechanistic interface with human systems. Using GUST+, Gusto has pioneered the world’s first digital map of host-microbiome ecological interactions.